1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Relapsed Multiple Myeloma Global Clinical Trials Review, H1, 2014

Relapsed Multiple Myeloma Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Relapsed Multiple Myeloma Global Clinical Trials Review, H1, 2014" provides data on the Relapsed Multiple Myeloma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Relapsed Multiple Myeloma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Relapsed Multiple Myeloma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Relapsed Multiple Myeloma Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents2
List of Tables 4
List of Figures 5
Introduction 6
Relapsed Multiple Myeloma 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Relapsed Multiple Myeloma 25
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Relapsed Multiple Myeloma Therapeutics Clinical Trials 32
Prominent Drugs 34
Latest Clinical Trials News on Relapsed Multiple Myeloma 35
Mar 05, 2014: Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma 35
Jan 22, 2014: Global Phase 3 Trial Commenced in Asia for Ixazomib, Takeda's Oral Proteasome Inhibitor 35
Dec 12, 2013: Clinical Study with Indatuximab Ravtansine (BT-062) in Multiple Myeloma shows good Tolerability and encouraging Efficacy in Combination with Lenalidomide and Dexamethasone 36
Dec 09, 2013: Interim Phase IIa Results for Spiegelmer Olaptesed Pegol in CLL and MM Studies 37
Aug 20, 2013: Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients 38
Clinical Trial Profiles 39
Clinical Trial Overview of Top Companies 39
Celgene Corporation 39
Clinical Trial Overview of Celgene Corporation 39
Amgen Inc. 43
Clinical Trial Overview of Amgen Inc. 43
Johnson and Johnson 45
Clinical Trial Overview of Johnson and Johnson 45
Takeda Pharmaceutical Company Limited 47
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 47
Novartis AG 49
Clinical Trial Overview of Novartis AG 49
Merck and Co., Inc. 51
Clinical Trial Overview of Merck and Co., Inc. 51
F. Hoffmann-La Roche Ltd. 52
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 52
Bristol-Myers Squibb Company 53
Clinical Trial Overview of Bristol-Myers Squibb Company 53
Array BioPharma Inc. 54
Clinical Trial Overview of Array BioPharma Inc. 54
AbbVie Inc. 55
Clinical Trial Overview of AbbVie Inc. 55
Clinical Trial Overview of Top Institutes / Government 56
National Cancer Institute 56
Clinical Trial Overview of National Cancer Institute 56
Mayo Clinic 58
Clinical Trial Overview of Mayo Clinic 58
The University of Texas M. D. Anderson Cancer Center 60
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 60
Memorial Sloan Kettering Cancer Center 61
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 61
University of Arkansas 62
Clinical Trial Overview of University of Arkansas 62
Washington University School of Medicine 63
Clinical Trial Overview of Washington University School of Medicine 63
Beijing Chao Yang Hospital 64
Clinical Trial Overview of Beijing Chao Yang Hospital 64
Fondazione Neoplasie Sangue Onlus 65
Clinical Trial Overview of Fondazione Neoplasie Sangue Onlus 65
Massachusetts General Hospital 66
Clinical Trial Overview of Massachusetts General Hospital 66
Five Key Clinical Profiles 67
Appendix 167
Abbreviations 167
Definitions 167
Research Methodology 168
Secondary Research 168
About GlobalData 169
Contact Us 169
Disclaimer 169
Source 170

List of Tables
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Region, 2014* 7
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Relapsed Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Relapsed Multiple Myeloma Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Relapsed Multiple Myeloma Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Relapsed Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 30
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 33
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 34
Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014* 39
Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 43
Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson and Johnson, 2014* 45
Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014* 47
Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 49
Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 51
Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 52
Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 53
Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Array BioPharma Inc., 2014* 54
Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014* 55
Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 56
Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014* 58
Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 60
Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 61
Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Arkansas, 2014* 62
Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014* 63
Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Beijing Chao Yang Hospital, 2014* 64
Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fondazione Neoplasie Sangue Onlus, 2014* 65
Relapsed Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 66

List of Figures
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Relapsed Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Relapsed Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 30
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 32
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 34
GlobalData Methodology 168

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.